What the July 2026 FDA Peptide Vote Did
Six peptides recommended, one rejected, and nothing legal to compound yet. The tallies, the April reclassification behind it, and what still has to happen.
Over two days in late July 2026, an FDA advisory committee voted on seven peptides. The coverage that followed was close to unanimous in reporting the outcome, and close to unanimous in getting its meaning wrong.
Nothing became legal to compound. That is worth stating first, because a great deal of marketing since has implied otherwise.
What the committee actually is
The Pharmacy Compounding Advisory Committee advises the FDA on which bulk drug substances belong on the 503A Bulks List — the set of ingredients a state-licensed pharmacy may use when compounding a medicine for an individual patient.
Two limits are built into that description and both matter.
It is advisory. The committee recommends; the FDA is not bound by the recommendation and retains discretion to accept, modify or reject it.
And the list it advises on is about compounding eligibility, not approval. A substance on the 503A Bulks List is one a pharmacist may work with on prescription. It has not been through the efficacy and safety review that produces a marketing authorisation. Those are different questions with different answers.
What happened in April, which is the part usually skipped
The vote did not come out of nowhere, and the step before it is more revealing than the vote itself.
On 15 April 2026 the FDA announced it would remove twelve peptides from Category 2 of the 503A bulk drug substances list — the category for substances presenting significant safety risks. The twelve were BPC-157, LL-37, DiHexa, emideltide (DSIP), Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax and TB-500.
The reason for the removal was procedural: the nominations had been withdrawn by the nominators. A substance cannot remain categorised in a review process that no longer has a live nomination behind it. That is an administrative consequence, not a scientific reassessment, and it was widely reported as though the FDA had softened its safety position.
It did not. Removal from Category 2 does not authorise compounding on its own, and it does not bring a substance within the interim enforcement policy that applies to Category 1 substances. The day after, on 16 April, the FDA published a Federal Register notice announcing the public meeting that became the July vote.
The votes
| Date | Substance | Outcome |
|---|---|---|
| 23 July 2026 | BPC-157 | Recommended |
| 23 July 2026 | KPV | Recommended |
| 23 July 2026 | TB-500 | Recommended |
| 23 July 2026 | MOTS-c | Recommended |
| 24 July 2026 | Epitalon | Recommended, 7–5 with one abstention |
| 24 July 2026 | Semax | Recommended, 8–5 |
| 24 July 2026 | Emideltide (DSIP) | Not recommended, 6–7 with one abstention |
Six recommended, one rejected. The margins on the second day are the interesting part: 7–5 and 6–7 are not consensus votes. This was a divided committee, and the single-vote difference between Epitalon being recommended and emideltide not being recommended is a thinner distinction than the outcomes suggest.
Why emideltide went the other way
The FDA’s position going in was that the safety and efficacy data do not support emideltide for the indications it is discussed for — insomnia, narcolepsy and opioid use disorder — that the compound is not adequately characterised, and that peptide-related impurities present a risk. Approved treatments already exist for those conditions, which raises the bar for adding an uncharacterised alternative.
Committee members raised the same themes across the other substances too: poor characterisation, and thin safety data. Those objections did not disappear on the substances that were recommended. They were outweighed.
What still has to happen
A recommendation is the first step of several, and the remaining ones are slow.
- The FDA has to act on it. The agency may accept, modify or reject the committee’s advice.
- The Secretary of Health and Human Services has to approve any addition to the 503A Bulks List formally.
- Final rulemaking has to be completed. Until it is, pharmacies may not compound these substances — and that remains true even if pharmaceutical-grade active ingredients become commercially available in the meantime.
Availability of an ingredient is not permission to use it. That gap between supply and legal status is exactly where the current marketing sits.
This describes United States compounding law and nothing else. It does not change the approval status of any of these substances anywhere, and it has no effect in the EU, where the legal framework is different. None of these compounds became an approved medicine in July 2026.
The separate question the vote did not touch
Even on the most favourable reading — the FDA accepts every recommendation, the Secretary signs, rulemaking completes — what would exist at the end is a set of substances a pharmacist may compound on prescription.
That is a supply-chain and pharmacy-practice change. It is not new evidence. The preclinical literature on BPC-157 is the same literature it was in June, the human data for MOTS-c are still observational, and none of these compounds acquired a published human half-life because a committee voted. A substance can be lawfully compoundable and still have no completed human efficacy trial behind it — those two facts are entirely compatible, and both are true here.
Reading regulatory news about this
Three habits are worth keeping, because this story will move again.
Check the date on anything you read; status here has changed three times in under a year. Check which list is being discussed — Category 1, Category 2, the 503A bulks list and the 503B bulks list are four different things. And check whether a source is describing a recommendation or a rule, because at the moment everything on the table is the former.
Frequently asked questions
Did the July 2026 vote make these peptides legal?
No. The Pharmacy Compounding Advisory Committee makes recommendations that do not bind the FDA. The Secretary of Health and Human Services must formally approve any addition to the 503A Bulks List, and pharmacies may not compound these substances until final rulemaking is in place. As of now, nothing has changed in what a pharmacy may lawfully compound.
Which peptides were recommended and which was rejected?
On 23 July 2026 the committee recommended BPC-157, KPV, TB-500 and MOTS-c. On 24 July it recommended Epitalon by 7 votes to 5 with one abstention, and Semax by 8 to 5. It declined to recommend emideltide, also known as DSIP, by 6 votes to 7 with one abstention.
Why was emideltide rejected?
The FDA briefing position was that there is a lack of safety and efficacy data supporting its use for insomnia, narcolepsy and opioid use disorder, that the compound is not adequately characterised, and that it carries risks from peptide-related impurities. Approved therapies already exist for those conditions.
What happened in April 2026, before the vote?
On 15 April 2026 the FDA announced it would remove twelve peptides from Category 2 of the 503A bulk drug substances list, because the nominations had been withdrawn by the nominators. This was procedural. Removal from Category 2 does not authorise compounding on its own and does not place a substance under the interim enforcement policy that applies to Category 1.
Sources
- FDA — Briefing Document, Pharmacy Compounding Advisory Committee meeting, July 2026
- Regulatory Affairs Professionals Society — FDA advisory committee backs two more peptides, rejects one for compounding list
- National Community Pharmacists Association — FDA advisory committee nominates six peptides for pharmacies to compound
- Orrick — FDA announces removal of 12 peptides from Category 2 and schedules PCAC meetings